118. Future Med Chem. 2018 Jun 1;10(11):1369-1388. doi: 10.4155/fmc-2017-0246. Epub2018 May 30.Recent advances in CDK inhibitors for cancer therapy.Heptinstall AB(1), Adiyasa I(1), Cano C(1), Hardcastle IR(1).Author information: (1)Newcastle Cancer Centre, School of Natural & Environmental Sciences, BedsonBuilding, Newcastle University, Newcastle, NE1 7RU, UK.Inhibition of CDKs is an attractive approach to cancer therapy due to their vitalrole in cell growth and transcription. Pan-CDK inhibitors have shown someclinical benefit, and trials are ongoing. Selective CDK4 and CDK6 inhibitors havebeen licensed for the treatment of hormone responsive, RB-positive breast cancer in combination with antihormonal agents. Selective inhibitors of CDKs 5, 7, 8, 9 and 12 have been identified across a range of chemotypes.DOI: 10.4155/fmc-2017-0246 PMID: 29846081 